The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with bivalirudin at a low dose, regularly monitoring platelet function, and adjusting the dose based on the results of platelet function assay (Multiplate®) to guarantee effective platelet P2Y12 pathway inhibition to achieve optimal platelet inhibition. Platelet function assays will be performed at various time points throughout the treatment timeframe. Cangrelor will then be stopped at the end of VA-ECMO support, and patients will be transitioned to oral P2Y12- inhibitors as per clinical guidelines.
Male or female patients aged ≥18 years;
ACS-related CS/CA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;
Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;
Written informed consent
Overt uncontrollable bleeding;
Suspected intra-cranial haemorrhage;
Patients who received any dose of any oral P2Y12-inhibitors;
Patients with known history of stroke or Transient Ischaemic Attack (TIA);